Epidarex Capital is an international early-stage life science venture capital fund that backs researchers and entrepreneurs.
Portfolio
4
companies
Clyde Biosciences
Clyde Biosciences develops technology to evaluate drug toxicity.
Curve Therapeutics
Curve Therapeutics develops a Microcycle platform for intracellular cancer drug discovery.
LUNAC Therapeutics
LUNAC Therapeutics develops advanced anticoagulants targeting activated Factor XII.
Macomics
Macomics develops novel immuno-therapies to overcome resistance in cancer treatments.
Mary Canning
Mary brings investment experience from her time as a partner at Epidarex Capital. She previously held associate and principal roles at the firm, following a stint as business manager at MRC Technology.
LinkedInElizabeth Roper
Partner at Epidarex Capital & Investor Director at Macomics
Sinclair Dunlop
Managing Partner
Sinclair is Managing Partner at Epidarex Capital. He previously worked as a Senior Associate at New Vantage Group and a Director at MASA Inc.
LinkedInPfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
Epidarex Capital led the seed round to help the Edinburgh spin-out advance its tumour-associated macrophage platform.
"Decades of research into macrophage biology, particularly that of tumour-associated macrophages, have made it very clear to me that this is an area of significant untapped potential for the development of novel cancer therapeutics. The creation of Macomics based on the research of my group at the University of Edinburgh provides the team with an exciting opportunity to develop new effective cancer drugs against macrophage targets, that will bring real clinical benefit to many more patients suffering from cancer."
Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.
"There is an urgent need for anticoagulant therapies with reduced bleeding risk. Our research has validated that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients."
Epidarex Capital led the Series A round for the drug toxicity testing specialist.
"Since its inception, Clyde Biosciences has been working hard to meet our clients’ needs in improving outcomes in drug development. This investment, led by Epidarex Capital, will help propel Clyde Biosciences to a new level, allowing us to strengthen our team, reinforce our commercial offering and broaden our geographic reach. We welcome the support of our investment partners and look forward to an exciting future."
